Drug
SAGE-547
SAGE-547 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)
Phase Distribution
Ph phase_2
3
50%
Ph phase_1
1
17%
Ph phase_3
1
17%
Phase Distribution
1
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Other(1)
Detailed Status
Completed5
unknown1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)
Trials by Status
unknown117%
completed583%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_3
A Study With SAGE-547 for Super-Refractory Status Epilepticus
NCT02477618
completedphase_1
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
NCT02052739
unknown
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
NCT02433314
completedphase_2
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
NCT02614547
completedphase_2
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
NCT02285504
Clinical Trials (6)
Showing 6 of 6 trials
NCT02477618Phase 3
A Study With SAGE-547 for Super-Refractory Status Epilepticus
NCT02052739Phase 1
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
NCT02433314
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
NCT02614547Phase 2
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
NCT02285504Phase 2
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
NCT02277106Phase 2
Evaluate SAGE-547 in Participants With Essential Tremor
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6